An Open-label, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Amgen
- 18 Jun 2019 Planned End Date changed from 16 Nov 2021 to 25 Apr 2021.
- 18 Jun 2019 Planned primary completion date changed from 24 Aug 2020 to 31 Jan 2020.
- 18 Jun 2019 Status changed from recruiting to active, no longer recruiting.